CN118742301A - 用于治疗或预防衰老相关病症的苯并二氢吡喃醇化合物 - Google Patents

用于治疗或预防衰老相关病症的苯并二氢吡喃醇化合物 Download PDF

Info

Publication number
CN118742301A
CN118742301A CN202380023421.3A CN202380023421A CN118742301A CN 118742301 A CN118742301 A CN 118742301A CN 202380023421 A CN202380023421 A CN 202380023421A CN 118742301 A CN118742301 A CN 118742301A
Authority
CN
China
Prior art keywords
compound
aging
use according
group
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380023421.3A
Other languages
English (en)
Chinese (zh)
Inventor
R·H·亨宁
G·克伦宁
A·C·范德格拉夫
D·H·斯沃特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sulfateq BV
Original Assignee
Sulfateq BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sulfateq BV filed Critical Sulfateq BV
Publication of CN118742301A publication Critical patent/CN118742301A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202380023421.3A 2022-02-28 2023-02-28 用于治疗或预防衰老相关病症的苯并二氢吡喃醇化合物 Pending CN118742301A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL2031091 2022-02-28
NL2031091A NL2031091B1 (en) 2022-02-28 2022-02-28 Chromanol compounds for treatment or prophylaxis of ageing and ageing-associated disorders
PCT/NL2023/050095 WO2023163596A1 (en) 2022-02-28 2023-02-28 Chromanol compounds for treatment or prophylaxis of ageing-associated disorders

Publications (1)

Publication Number Publication Date
CN118742301A true CN118742301A (zh) 2024-10-01

Family

ID=83271289

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380023421.3A Pending CN118742301A (zh) 2022-02-28 2023-02-28 用于治疗或预防衰老相关病症的苯并二氢吡喃醇化合物

Country Status (10)

Country Link
US (1) US20250177384A1 (https=)
EP (1) EP4486317A1 (https=)
JP (1) JP2025506844A (https=)
CN (1) CN118742301A (https=)
AU (1) AU2023225518A1 (https=)
CA (1) CA3252944A1 (https=)
CL (1) CL2024002555A1 (https=)
NL (1) NL2031091B1 (https=)
WO (1) WO2023163596A1 (https=)
ZA (1) ZA202406418B (https=)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006105806A1 (en) 2005-04-07 2006-10-12 Miso Sabovic Delaying the ageing process and disorders caused by ageing
EP2680838A1 (en) 2011-02-28 2014-01-08 Farmicom Pharmaceutical Company D.O.O. TREATMENT OF ARTERIAL AGEING BY COMBINATION OF RAAS INHIBITOR AND HMG-CoA REDUCTASE INHIBITOR
KR102137450B1 (ko) 2012-07-12 2020-07-27 콘드리온 아이피 비.브이. 미토콘드리아 질환을 치료하기 위한 크로마닐 유도체
NL2010010C2 (en) 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
WO2015148522A1 (en) 2014-03-24 2015-10-01 Seals Douglas R Methods for treatment of vascular endothelial dysfunction using nicotinamide mononucleotide
NL2013012B1 (en) * 2014-06-17 2016-07-05 Sulfateq Bv Compounds for the treatment of chronic obstructive airway diseases.
US10815211B2 (en) 2015-10-08 2020-10-27 Khondrion Ip B.V. Compounds for treating mitochondrial disease
ES2959243T3 (es) * 2017-04-05 2024-02-22 Khondrion Ip B V Nuevo tratamiento de enfermedades mitocondriales
EP3672593B1 (en) * 2017-08-25 2024-12-18 Sulfateq B.V. Medicaments for the treatment of vasoconstriction related diseases or disorders
WO2019038360A1 (en) * 2017-08-25 2019-02-28 Sulfateq B.V. 6-CHROMANOL DERIVATIVES FOR USE AS A MEDICINAL PRODUCT
NL2024431B1 (en) * 2019-12-11 2021-09-07 Sulfateq Bv Compounds for treatment of alzheimer’s disease
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure

Also Published As

Publication number Publication date
US20250177384A1 (en) 2025-06-05
AU2023225518A1 (en) 2024-09-12
EP4486317A1 (en) 2025-01-08
NL2031091B1 (en) 2023-09-07
CL2024002555A1 (es) 2025-01-10
JP2025506844A (ja) 2025-03-13
WO2023163596A1 (en) 2023-08-31
ZA202406418B (en) 2025-11-26
CA3252944A1 (en) 2023-08-31

Similar Documents

Publication Publication Date Title
JP4491136B2 (ja) 関節症を治療するためのファルネシルタンパク質トランスフェラーゼ阻害剤
ES2741439T3 (es) Compuestos aromáticos sustituidos
WO2006120176A2 (en) Combination of the pde4 inhibitor roflumilast and a tetrahydrobiopterin derivative
EA017510B1 (ru) Ингибиторы mpo для лечения множественной системной атрофии
JP7695246B2 (ja) アルツハイマー病の治療のための化合物
CN116322661B (zh) 用于治疗心力衰竭的苯并二氢吡喃醇化合物
US20250025444A1 (en) Treatment of neurodegenerative diseases via administration of buntanetap and a phosphodiesterase inhibitor
CN118742301A (zh) 用于治疗或预防衰老相关病症的苯并二氢吡喃醇化合物
JP7169580B2 (ja) 線維症治療用医薬組成物
CN106714842B (zh) 包含双重PI3K δ-γ激酶抑制剂和皮质类固醇的治疗方法及组合物
EP4051257A1 (en) Combination therapy having antioxydant properties
US10624883B2 (en) Pulmonary hypertension preventative or therapeutic agent containing component exhibiting selenoprotein P activity-inhibiting effect
HK40115454A (zh) 用於治疗或预防衰老相关病症的苯并二氢吡喃醇化合物
US20070049599A1 (en) Use of bh4 for the treatment of respiratory diseases
KR20170005539A (ko) 디피리다몰을 유효 성분으로 함유하는 신장 질환 치료용 의약 조성물
AU2020376223B2 (en) Combination therapy having antioxydant properties
JP2015160847A (ja) 小分子のキサンチンオキシダーゼ阻害剤および使用方法
WO2025221289A1 (en) Treatment of diseases via administration of buntanetap and a phosphodiesterase inhibitor
WO2024137780A1 (en) Pank modulators and methods of treatment using same
HK40121343A (zh) 治疗特发性肺纤维化的方法
FR3164896A1 (fr) Mébévérine pour son utilisation dans le traitement des maladies auto-immunes
JP2019182845A (ja) キヌレニンアミノトランスフェラーゼ２（ｋａｔ２）阻害剤
WO2014162106A1 (fr) Nouveaux derives de chalcone presentant une activite anti-allergique
JP2000034287A (ja) 抗真菌剤
HK1145141B (en) Mipo inhibitors for the treatment of huntington's disease and multiple system atrophy

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40115454

Country of ref document: HK